RNAi as new class of nanomedicines

Monika Dominska, Derek M Dykxhoorn

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

RNA interference (RNAi)-based gene-silencing technologies provide a novel approach for the treatment of a variety of diseases through the sequence-specific silencing of gene expression. The application of small interfering RNA (siRNA) as potential therapeutic agents requires the development of clinically feasible delivery strategies that enhance their pharmacological properties. To be efective, siRNAs must be delivered to and taken up by specific target cells and tissues, enter the cytoplasm, and associate with the RNA-induced silencing complex (RISC) to guide the sequence-specific cleavage of appropriate messenger RNA (mRNA). This chapter will focus on recent progress made in the development of safe and efective therapeutic strategies for the siRNA-based silencing of gene expression.

Original languageEnglish
Title of host publicationHandbook of Harnessing Biomaterials in Nanomedicine
PublisherPan Stanford Publishing Pte. Ltd.
Pages163-197
Number of pages35
ISBN (Print)9789814316460
DOIs
StatePublished - Jan 31 2012

Fingerprint

Nanomedicine
Medical nanotechnology
RNA Interference
RNA
Gene expression
Small Interfering RNA
RNA-Induced Silencing Complex
Gene Expression
Gene Silencing
Cytoplasm
Genes
Pharmacology
Tissue
Technology
Messenger RNA
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)
  • Engineering(all)

Cite this

Dominska, M., & Dykxhoorn, D. M. (2012). RNAi as new class of nanomedicines. In Handbook of Harnessing Biomaterials in Nanomedicine (pp. 163-197). Pan Stanford Publishing Pte. Ltd.. https://doi.org/10.4032/9789814364270

RNAi as new class of nanomedicines. / Dominska, Monika; Dykxhoorn, Derek M.

Handbook of Harnessing Biomaterials in Nanomedicine. Pan Stanford Publishing Pte. Ltd., 2012. p. 163-197.

Research output: Chapter in Book/Report/Conference proceedingChapter

Dominska, M & Dykxhoorn, DM 2012, RNAi as new class of nanomedicines. in Handbook of Harnessing Biomaterials in Nanomedicine. Pan Stanford Publishing Pte. Ltd., pp. 163-197. https://doi.org/10.4032/9789814364270
Dominska M, Dykxhoorn DM. RNAi as new class of nanomedicines. In Handbook of Harnessing Biomaterials in Nanomedicine. Pan Stanford Publishing Pte. Ltd. 2012. p. 163-197 https://doi.org/10.4032/9789814364270
Dominska, Monika ; Dykxhoorn, Derek M. / RNAi as new class of nanomedicines. Handbook of Harnessing Biomaterials in Nanomedicine. Pan Stanford Publishing Pte. Ltd., 2012. pp. 163-197
@inbook{d51c9e97e4474e52a3ac1286410d5656,
title = "RNAi as new class of nanomedicines",
abstract = "RNA interference (RNAi)-based gene-silencing technologies provide a novel approach for the treatment of a variety of diseases through the sequence-specific silencing of gene expression. The application of small interfering RNA (siRNA) as potential therapeutic agents requires the development of clinically feasible delivery strategies that enhance their pharmacological properties. To be efective, siRNAs must be delivered to and taken up by specific target cells and tissues, enter the cytoplasm, and associate with the RNA-induced silencing complex (RISC) to guide the sequence-specific cleavage of appropriate messenger RNA (mRNA). This chapter will focus on recent progress made in the development of safe and efective therapeutic strategies for the siRNA-based silencing of gene expression.",
author = "Monika Dominska and Dykxhoorn, {Derek M}",
year = "2012",
month = "1",
day = "31",
doi = "10.4032/9789814364270",
language = "English",
isbn = "9789814316460",
pages = "163--197",
booktitle = "Handbook of Harnessing Biomaterials in Nanomedicine",
publisher = "Pan Stanford Publishing Pte. Ltd.",

}

TY - CHAP

T1 - RNAi as new class of nanomedicines

AU - Dominska, Monika

AU - Dykxhoorn, Derek M

PY - 2012/1/31

Y1 - 2012/1/31

N2 - RNA interference (RNAi)-based gene-silencing technologies provide a novel approach for the treatment of a variety of diseases through the sequence-specific silencing of gene expression. The application of small interfering RNA (siRNA) as potential therapeutic agents requires the development of clinically feasible delivery strategies that enhance their pharmacological properties. To be efective, siRNAs must be delivered to and taken up by specific target cells and tissues, enter the cytoplasm, and associate with the RNA-induced silencing complex (RISC) to guide the sequence-specific cleavage of appropriate messenger RNA (mRNA). This chapter will focus on recent progress made in the development of safe and efective therapeutic strategies for the siRNA-based silencing of gene expression.

AB - RNA interference (RNAi)-based gene-silencing technologies provide a novel approach for the treatment of a variety of diseases through the sequence-specific silencing of gene expression. The application of small interfering RNA (siRNA) as potential therapeutic agents requires the development of clinically feasible delivery strategies that enhance their pharmacological properties. To be efective, siRNAs must be delivered to and taken up by specific target cells and tissues, enter the cytoplasm, and associate with the RNA-induced silencing complex (RISC) to guide the sequence-specific cleavage of appropriate messenger RNA (mRNA). This chapter will focus on recent progress made in the development of safe and efective therapeutic strategies for the siRNA-based silencing of gene expression.

UR - http://www.scopus.com/inward/record.url?scp=84882031522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882031522&partnerID=8YFLogxK

U2 - 10.4032/9789814364270

DO - 10.4032/9789814364270

M3 - Chapter

SN - 9789814316460

SP - 163

EP - 197

BT - Handbook of Harnessing Biomaterials in Nanomedicine

PB - Pan Stanford Publishing Pte. Ltd.

ER -